AMD

Previously treated patients showed significantly reduced treatment burden.

At Angiogenesis, Dr SriniVas R. Sadda discusses how choriocapillaris may predict the rate of progression of atrophy.

In a presentation at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation and Degeneration 2022 Virtual Edition, Dr Glenn J. Jaffe noted that the analysis showed, for the first time, a decreased growth rate in the central foveal area by a therapeutic intervention when compared with sham treatment.

Dr Nadia K. Waheed reviews the latest updates on the FOCUS trial, evaluating AAV-based viral vector GT005 for the treatment of geographic atrophy.

This study showed that an investigational subretinal implant, CPCB-RPE1, containing allogeneic human embryonic stem cell-derived RPE cells, was safe and well-tolerated by patients with dry AMD.

Dr David S. Boyer describes how blocking Connexin-43 may improve the retinal vascular system function in patients with diabetes, potentially creating a future of oral medication for treatment of diabetic retinopathy and AMD.

A once-daily oral drug targets inflammatory processes and thus far has been found to be well tolerated in a Phase 2 safety trial.

A new home telemedicine system generates valuable data on disease and the dynamics of fluid exudation.

A team of investigators are working on a simple test that may someday identify those who can stop therapy.

Genentech’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.

Dr Firas Rahhal discusses Outlook Therapeutics’ Phase 3 pivotal NORSE TWO trial for ONS-5010.

A University of California Davis, United States, study shows that small serving of the fruit increased protective pigments in the eye.

Current options, challenges in developing novel therapies.

Susvimo, formerly called the Port Delivery System with ranibizumab, is a first-of-its-kind therapeutic approach for wet AMD and may help people with the disease maintain their vision with as few as two treatments per year.

Dr Arshad Khanani reported at ASRS 2021 that the Port Delivery System with ranibizumab, an investigational product that continuously delivers ranibizumab intravitreally, achieved results similar to those in patients treated with monthly ranibizumab injections for nAMD.

During a presentation at the EURETINA 2021 Virtual Congress, Dr Daniel Jones discussed GA and emphasized the need for additional study to gain a better understanding of the burden experienced by patients.

In a presentation at the EURETINA 2021 Virtual Congress, Dr Cristina Cristian noted that an injection of brolucizumab treatment in patients with neovascular age-related macular degeneration led to a median improvement in visual acuity (VA) of 10.5 letters and the drug was well-tolerated.

During a presentation at the EURETINA 2021 Virtual Congress, Dr Anat Loewenstein discussed how artificial intelligence can optimize optical coherence tomography.

Speaking during the EURETINA 2021 Virtual Congress, Dr Marta Belmonte-Grau discussed the potential risk for posterior capsular rupture during cataract surgery.

Fluorescence lifetime imaging ophthalmoscopy may be useful to monitor the progression of AMD as well as the effectiveness of treatment approaches.

Why investigators are recognising AMD as a disease spectrum rather than a single entity.

Following a discussion regarding drug delivery challenges in retinal disease, a panel of global experts suggest what types of technological requirements and improvements they would like to see occur in the field.

Challenges associated with delivering therapies currently available to treat retinal disorders and methods being explored to improve drug delivery to patients.

Drawbacks and challenges associated with the administration of anti-VEGF injections currently available to treat retinal diseases.

Dr Mariya Moosajee highlights therapies approved as well as under study to improve treatment for patients with inherited retinal disease.

A discussion regarding the roles of various treatments available for diabetic macular edema and considerations for selecting and sequencing therapy.

An overview of the current treatment landscape for age-related macular degeneration and factors that impact treatment selection.

Types of tests and criteria that can be used to diagnose conditions such as age-related macular degeneration, diabetic macular edema, and inherited retinal disease.

A panel of global experts who treat patients with retinal diseases suggest causes of age-related macular degeneration, diabetic macular edema, and inherited retinal disease.

Anat Loewenstein, MD, MHA, explores dual Ang-2/VEGF-A inhibition in the management of diabetic macular edema and exudative age-related macular degeneration.